1
|
Kaufmann DK, Raczak G, Szwoch M, Wabich E, Świątczak M, Daniłowicz-Szymanowicz L. Baroreflex sensitivity but not microvolt T-wave alternans can predict major adverse cardiac events in ischemic heart failure. Cardiol J 2022; 29:1004-1012. [PMID: 33001423 PMCID: PMC9788737 DOI: 10.5603/cj.a2020.0129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Revised: 07/23/2020] [Accepted: 08/28/2020] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Major adverse cardiovascular events (MACE) constitutes the main cause of morbidity and mortality in ischemic heart failure (HF) patients. The prognostic value of the autonomic nervous system parameters and microvolt T-wave alternans (MTWA) in this issue has not been identified to date. The aim herein, was to assess the usefulness of the abovementioned parameters in the prediction of MACE in HF patients with left ventricular systolic dysfunction of ischemic origin. METHODS Baroreflex sensitivity (BRS), heart rate variability (HRV), MTWA and other well-known clinical parameters were analyzed in 188 ischemic HF outpatients with left ventricular ejection fraction (LVEF) ≤ 50%. During 34 (14-71) months of follow-up, 56 (30%) endpoints were noted. RESULTS Univariate Cox analyses revealed BRS (but not HRV), MTWA, age, New York Heart Association functional class III, LVEF, implantable cardioverter-defibrillator presence, use of diuretics and antiarrhythmic drugs, diabetes, and kidney insufficiency were defined as significant predictors of MACE. Pre-specified cut-off values for MACE occurrence for the aforementioned continuous parameters (age, LVEF, and BRS) were: ≥ 72 years, ≤ 33%, and ≤ 3 ms/mmHg, respectively. In a multivariate Cox analysis only BRS (HR 2.97, 95% CI 1.35-6.36, p < 0.006), and LVEF (HR 1.98, 95% CI 0.61-4.52, p < 0.038) maintained statistical significance in the prediction of MACE. CONCLUSIONS Baroreflex sensitivity and LVEF are independent of other well-known clinical parameters in the prediction of MACE in patients with HF of ischemic origin and LVEF up to 50%. BRS ≤ 3 ms/mmHg and LVEF ≤ 33% identified individuals with the highest probability of MACE during the follow-up period.
Collapse
|
3
|
Greig D, Austin PC, Zhou L, Tu JV, Pang PS, Ross HJ, Lee DS. Ischemic Electrocardiographic Abnormalities and Prognosis in Decompensated Heart Failure. Circ Heart Fail 2014; 7:986-93. [DOI: 10.1161/circheartfailure.114.001460] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Background—
Identification of coronary ischemia may enable targeted diagnostic and therapeutic strategies for acute heart failure. We determined the risk of 30-day mortality associated with ischemic ECG abnormalities in patients with acute heart failure.
Methods and Results—
Among 8772 patients (53.4% women, median 78 years [Q1, Q3: 68,84]) presenting with acute heart failure to 86 hospital emergency departments in Ontario, Canada, Q-waves, T-wave inversion, or ST-depression were present in 51.8% of subjects. However, presence of ST-depression was the only finding associated with 30-day mortality with adjusted odds ratio 1.24 (95% confidence interval [CI], 1.02–1.50). Using continuous net reclassification improvement, addition of ST-depression to the Emergency Heart failure Mortality Risk Grade model reclassified 16.9% of patients overall, and 29.3% of those with a history of ischemic heart disease (both
P
<0.001). By adding ST-depression to the model, the Emergency Heart failure Mortality Risk Grade was extended to predict 30-day death with high discrimination (
c
-statistic 0.801), with 0.57% mortality rate in the lowest risk decile. Adjusted odds ratios for 30-day mortality were 2.81 (95% CI, 1.48–5.31;
P
=0.002) in quintile 2, 7.41 (95% CI, 4.13–13.30;
P
<0.001) in quintile 3, and 14.47 (95% CI, 8.20–25.54;
P
<0.001) in quintile 4 compared with the lowest risk quintile. When the highest risk quintile was subdivided into 2 equally sized risk strata (deciles 9 and 10), the adjusted odds ratios for 30-day mortality were 27.20 (95% CI, 15.33–48.27;
P
<0.001) in decile 9 and 58.96 (95% CI, 33.54–103.65;
P
<0.001) in highest risk decile 10.
Conclusions—
Presence of ST-depression on the ECG reclassified risk of 30-day mortality in patients with acute heart failure, identifying both high- and low-risk subsets.
Collapse
Affiliation(s)
- Douglas Greig
- From the Division of Cardiology, Peter Munk Cardiac Centre (D.G., H.J.R., D.S.L.) and Joint Department of Medical Imaging (D.S.L.), University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada (D.G., P.C.A., J.V.T., H.J.R., D.S.L.); Division of Cardiovascular Diseases, School of Medicine, P. Universidad Católica de Chile, Santiago, Chile (D.G.); Institute for Clinical Evaluative Sciences, Toronto, Canada (P.C.A., L.Z., J.V.T., D.S.L.); Institute of Health Policy, Management,
| | - Peter C. Austin
- From the Division of Cardiology, Peter Munk Cardiac Centre (D.G., H.J.R., D.S.L.) and Joint Department of Medical Imaging (D.S.L.), University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada (D.G., P.C.A., J.V.T., H.J.R., D.S.L.); Division of Cardiovascular Diseases, School of Medicine, P. Universidad Católica de Chile, Santiago, Chile (D.G.); Institute for Clinical Evaluative Sciences, Toronto, Canada (P.C.A., L.Z., J.V.T., D.S.L.); Institute of Health Policy, Management,
| | - Limei Zhou
- From the Division of Cardiology, Peter Munk Cardiac Centre (D.G., H.J.R., D.S.L.) and Joint Department of Medical Imaging (D.S.L.), University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada (D.G., P.C.A., J.V.T., H.J.R., D.S.L.); Division of Cardiovascular Diseases, School of Medicine, P. Universidad Católica de Chile, Santiago, Chile (D.G.); Institute for Clinical Evaluative Sciences, Toronto, Canada (P.C.A., L.Z., J.V.T., D.S.L.); Institute of Health Policy, Management,
| | - Jack V. Tu
- From the Division of Cardiology, Peter Munk Cardiac Centre (D.G., H.J.R., D.S.L.) and Joint Department of Medical Imaging (D.S.L.), University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada (D.G., P.C.A., J.V.T., H.J.R., D.S.L.); Division of Cardiovascular Diseases, School of Medicine, P. Universidad Católica de Chile, Santiago, Chile (D.G.); Institute for Clinical Evaluative Sciences, Toronto, Canada (P.C.A., L.Z., J.V.T., D.S.L.); Institute of Health Policy, Management,
| | - Peter S. Pang
- From the Division of Cardiology, Peter Munk Cardiac Centre (D.G., H.J.R., D.S.L.) and Joint Department of Medical Imaging (D.S.L.), University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada (D.G., P.C.A., J.V.T., H.J.R., D.S.L.); Division of Cardiovascular Diseases, School of Medicine, P. Universidad Católica de Chile, Santiago, Chile (D.G.); Institute for Clinical Evaluative Sciences, Toronto, Canada (P.C.A., L.Z., J.V.T., D.S.L.); Institute of Health Policy, Management,
| | - Heather J. Ross
- From the Division of Cardiology, Peter Munk Cardiac Centre (D.G., H.J.R., D.S.L.) and Joint Department of Medical Imaging (D.S.L.), University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada (D.G., P.C.A., J.V.T., H.J.R., D.S.L.); Division of Cardiovascular Diseases, School of Medicine, P. Universidad Católica de Chile, Santiago, Chile (D.G.); Institute for Clinical Evaluative Sciences, Toronto, Canada (P.C.A., L.Z., J.V.T., D.S.L.); Institute of Health Policy, Management,
| | - Douglas S. Lee
- From the Division of Cardiology, Peter Munk Cardiac Centre (D.G., H.J.R., D.S.L.) and Joint Department of Medical Imaging (D.S.L.), University Health Network, Toronto, Canada; University of Toronto, Toronto, Canada (D.G., P.C.A., J.V.T., H.J.R., D.S.L.); Division of Cardiovascular Diseases, School of Medicine, P. Universidad Católica de Chile, Santiago, Chile (D.G.); Institute for Clinical Evaluative Sciences, Toronto, Canada (P.C.A., L.Z., J.V.T., D.S.L.); Institute of Health Policy, Management,
| |
Collapse
|